In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 39 for your search:
Drug:  pegfilgrastim
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FIL_VERAL12, NCT01805557

2.

Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-01738, CDR0000659024, GOG-0250, U10CA027469, NCT01012297

3.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GOG-0277, NCI-2012-00249, CDR0000724874, IRCI 001, U10CA027469, NCT01533207

5.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: HHPG-19K -III-02, NCT01560195

6.

Phase: Phase III
Type: Supportive care
Status: Active
Age: 65 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: XM22-ONC-305, 2013-001284-23, NCT02044276

7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-1012, 3R01CA137488, 1012, SOL-05025-L, OHSU-SOL-05025-L, NCT00293475

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 60
Sponsor: Other
Protocol IDs: CDR0000572096, USCTU-UR1002-GEM-TIP, EU-20769, EUDRACT-2004-004804-19, UR1002-Gem-TIP, NCT00551122

9.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC078E, P30CA015083, RV-NHL-PI-0325, 07-007992, NCI-2009-01196, MAYO-MC078E, CELGENE-RV-NHL-PI-0325, NCT00670358

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0065, NCI-2012-01779, NCT01169636

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCI-2011-01123, NCT01371630

13.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI# 12-104, NCT01879085

14.

Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20020715, UCLA-0412010-01, AMGEN-20020715, NCT00094809

15.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: CDR0000454505, DSHNHL-2004-1, EU-20536, DSHNHL-CHOP-R-ESC, EUDRACT-2005-00529-68, NCT00290667

16.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LY-012006, NCT00333008

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Ethics committee 079.06, NSD 14918, NCT00496795

18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000562751, RPCI-I-83106, I 83106, NCT00524628

19.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and under
Sponsor: Other
Protocol IDs: CHU-0041, NCT00751894

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: CDR0000636032, IB-FRAIL06, INCA-RECF0892, IB-2008-25, EUDRACT-2008-001506-16, FRAIL 06, NCT00911183

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SAKK 16/08, SWS-SAKK-16/08, EU-21002, CDR0000664070, NCT01059188

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0598, NCT01319981

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-0334, NCI-2012-01096, NCT01624805

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: J1214, Nilo Azad, MD, NA_00069666, NCT01639131

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC-627-02, NCT01648322
1   
New Search